Back

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in special populations - cardio-oncology (1) Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Cardiac manifestations in patients with systemic sclerosis
Associate Professor V. Stoickov (Niska Banja, RS)
Abstract Slides Video
Presentation thumbnail
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Doctor A. Abiodun (London, GB)
Abstract Slides Video
Presentation thumbnail
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
Miss E. Polomski (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology
Doctor V. Quagliariello (Naples, IT)
Abstract Slides Video
Presentation thumbnail
The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction
Doctor M. Dominique Joseph (Port-au-Prince, HT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in special populations - cardio-oncology (1)

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
thumbnail
Congress Presentation
The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources